Fresenius

Novo’s Ozempic shows promise in kidney disease, but DaVita questions its real-world benefits

Novo Nordisk’s GLP-1 blockbuster Ozempic appears to be making significant strides in the treatment of chronic kidney disease (CKD), potentially ...